[Comparative study of molecular response of first-line and second-line nilotinib in patients with chronic-phase chronic myelogenous leukemia]

Zhonghua Xue Ye Xue Za Zhi. 2019 Jun 14;40(6):522-525. doi: 10.3760/cma.j.issn.0253-2727.2019.06.014.

[Article in Chinese]

¹ Jinzhou Medical University, Jinzhou 121001, China; Hematology of Department, Henan Province People's Hospital, Zhengzhou 450003, China.
² Hematology of Department, Xinyang Central Hospital, Xinyang 464000, China.
³ Hematology of Department, Henan Province People's Hospital, Zhengzhou 450003, China.
⁴ Hematology of Department, Henan Province People's Hospital, Zhengzhou 450003, China; Institute of Hematology, Henan Province People's Hospital, Zhengzhou 450003, China.

No abstract available

MeSH terms